Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs

International Immunology

Volumn 19, Issue 10, 2007, Pages 1223-1234

  Wong, Raymond M ^a,c   Scotland, Ron R ^a   Lau, Roy L ^a   Wang, Changyu ^b   Korman, Alan J ^b   Kast, W M ^a   Weber, Jeffrey S ^a,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Medarex Inc   (United States)

^c MannKind Corporation   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; Co stimulation; Immunotherapy; Lymphocyte; Vaccine

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 100; MELANOMA ANTIGEN; MELANOMA ANTIGEN RECOGNIZED BY T CELLS 1 PROTEIN; MEMBRANE PROTEIN; PROGRAMMED DEATH 1 PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPHOCYTE CULTURE; LYMPHOCYTE FUNCTION; MELANOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, NEOPLASM; APOPTOSIS REGULATORY PROTEINS; CYTOKINES; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34848900497     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxm091     Document Type: Article

References (50)

1. Ishida, Y., Agate, Y, Shibahara, K. and Honjo, T. 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene, superfamily, upon programmed cell death. EMBO J. 11:3887.
2. Keir, M. E., Latchman, Y. E., Freeman, G. J. and Sharpe, A. H. 2005. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J. Immunol. 175:7372.
3. Agata, Y, Kawasaki, A., Nishimura, H. et al. 1996. Expression of the PD-1 antigen on the surface of stimulated mouse T and, B lymphocytes. Int. Immunol. 8:765.
4. Nishimura, H. and Honjo, T. 2001. PD-1: An inhibitory immunoreceptor involved in peripheral tolerance. Trend Immunol. 22:265.
5. Greenwald, R. J., Freeman, G. J. and Sharpe, A. H. 2005. The B7 family revisited. Annu. Rev. Immunol. 23:515.
6. Chen, L. 2004. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4:336.
7. Liang, S. C., Latchman, Y. E., Buhlmann, J. E. et al. 2003. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33:2706.
8. Brown, J. A., Dorfman, D. M., Ma F. R. et al. 2003. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170:1257.
9. Sharpe, A. H., Wherry, E. J., Ahmed, R. and Freeman, G. J. 2007 The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8:239.
10. Barber, D. L., Wherry, E. J., Masopust, D. et al. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682.
11. Blank, C., Kuball, J., Voelki, S. et al. 2006. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int. J. Cancer. 119:317.
12. Petrovas, C., Casazza, J. P., Brenchley, J. M. et al. 2006. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J. Exp. Med. 203:2281.
13. Trautmann, L, Janbazian, L., Chomont, N. et al. 2006. Upregulation of PD-1 expression on HIV-specific CD8(+) T cells leads to reversible immune dysfunction. Nat. Med. 12:1198.
14. Urbani, S., Amadei, B., Tola, D. et al. 2006. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J. Virol. 80: 11398.
15. Day, C. L., Kaufmann, D. E., Kiepiela, P. et al. 2006, PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350.
16. Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H. and Riley, J. L. 2004. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173:945.
17. Mocellin, S., Rossi, C. R., Nitti, D., Lise, M. and Marincola, F. M. 2003. Dissecting tumor responsiveness to immunotherapy: The experience of peptide-based melanoma vaccines. Biochim. Biophys. Acta. 1653:61.
18. Rosenberg, S. A., Yang, J. C. and Restifo, N. P. 2004. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10:909.
19. Morse, M. A., Chui, S., Hobeika, A., Lyerly, H. K. and Clay, T 2005. Recent developments in therapeutic cancer vaccines. Nat. Clin. Pract. Oncol. 2:108.
20. Rubio, V., Stuge, T. B., Singh, N. et al. 2003. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 9:1377.
21. Stuge, T. B., Holmes, S. P., Saharan, S. et al. 2004. Diversity and recognition efficiency of T cell responses to cancer. PLoS Med. 1:e28.
22. Kohrt, H. E., Shu, C. T, Stuge, T. B., Holmes, S. P., Weber, J. and Lee, P. P. 2005. Rapid assessment of recognition efficiency and functional capacity of antigen-specific T-cell responses. J. Immunother. 28:297.
23. Hodge, J. W., Chakraborty, M., Kudo-Saito, C., Garnett, C. T. and Schlom, J. 2005. Multiple costimulatory modalities enhance CTL avidity. J. Immunol. 174:5994.
24. Lee, P., Wang, F., Kuniyoshi, J. et al. 2001. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19:3836.
25. Lau, R., Wang, F., Jeffery, G. et al. 2001. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J. Immunother. 24:66.
26. Shortman, K. and Liu, Y. J. 2QO2. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2:151.
27. Sallusto, F, Cella, M., Danieli, C. and Lanzavecchia, A. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products. J. Exp. Med. 182:389.
28. Seo, S. K., Seo, H. M., Jeong, H. Y. et al. 2006. Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response. Immunol. Lett. 102:222.
29. Kawakami, Y., Eliyahu, S., Delgado, C. H. et al. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl Acad. Sci. USA. 91:6458.
30. Kawakami, Y., Eliyahu, S., Jennings, C. et al. 1995. Recognition of multiple epitopes in the human melanoma antigen gp 100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
31. Kawakami, Y., Eliyahu, S., Sakaguchi, K. et al. 994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
32. Friberg, D. D., Bryant, J. L. and Whiteside, T. L. 1996. Measurements of natural killer (NK) activity and NK-cell quantification. Methods 9:316.
33. Zeh, H. J. III, Perry-Lalley, D., Dudley, M. E., Rosenberg, S. A. and Yang, J. C. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162:989.
34. Dutoit, V, Rubio-Godoy, V, Dietrich, P. Y. et al. 2001. Heterogeneous T-cell response to MAGE-A10(254-262): High avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res. 61:5850.
35. Bullock, T. N., Mullins, D. W., Colella, T. A. and Engelhard, V. H. 2001. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class l-transgenic mice. J. Immunol. 167:5824.
36. O'Connor, D. H., Allen, T. M., Vogel, T. U. et al. 2002. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat. Med. 8:493.
37. Molldrem, J. J., Lee, P. P., Kant, S. et al. 2003. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 111:639.
38. Yang, S., Linette, G. P., Longerich, S. and Haluska, F. G. 2002. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after. stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J. Immunol. 169:531.
39. Trapani, J. A. and Smyth, M. J. 2002. Functional significance of the perforin/granzyme cell death pathway. Nat. Rev. Immunol. 2:735.
40. Tatsumi, T., Kierstead, L. S., Ranieri E. et al. 2002. Disease-associated bias in T helper type, 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J. Exp. Med. 196:619.
41. Peggs, K. S. and Allison, J.P. 2005. Co-stimulatory pathways in lymphocyte regulation: The immunoglobulin superfamily. Br. J. Haematol. 130:809.
42. Phan, G. Q., Yang, J. C., Sherry, R. M. et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA. 100:8372.
43. Sanderson, K., Scotland, R., Lee, P. et al. 2005. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected, stages III and IV melanoma. J. Clin. Oncol. 23:741.
44. Attia, P., Phan, G. Q., Maker, A. V. et al. 2005. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23:6043.
45. Parry, R. V., Chemnitz, J. M., Frauwirth, K. A. et al. 2005. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25:9543.
46. Kumaraguru, U., Suvas, S., Biswas, P. S., Azkur, A. K. and Rouse, B. T. 2004. Concomitant helper response rescues otherwise low avidity CD8+ memory CTLs to become efficient effectors in vivo. J. Immunol. 172:3719.
47. Dong, H., Strome, S. E., Salomao, D. R. et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 8:793.
48. Muhlbauer, M., Fleck, M., Schutz, C. et al. 2006. PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J. Hepatol. 45:520.
49. Dudley, M. E., Wunderlich, J. R., Yang, J. C. et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23:2346.
50. Yee, C., Thompson, J. A., Byrd, D. et al. 2002. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl Acad. Sci. USA. 99:16168.